Outcome of the Board Meeting held on 13th August, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The board approved unaudited standalone and consolidated results for the quarter ended 30 June 2025. Standalone net sales fell sharply to Rs. 29.79 lakh from Rs. 66.56 lakh in the same quarter last year, a decline of about 55%. The company reported a standalone net loss of Rs. 28.26 lakh, wider than the Rs. 24.30 lakh loss in Q1FY25. On a consolidated basis (including two subsidiaries – 1908 E-Ventures Pvt Ltd and Anamoticals Ador India Pvt Ltd), net sales were Rs. 29.78 lakh and the loss for the quarter was Rs. 28.32 lakh. Full-year FY25 standalone loss stood at Rs. 63.55 lakh, while consolidated FY25 loss was Rs. 316.58 lakh, heavily impacted by a Rs. 262.37 lakh exceptional item in Q4FY25. Paid-up equity share capital increased to Rs. 956.09 lakh from Rs. 467.36 lakh, indicating a recent equity fundraise.
Sharp revenue contraction and persistent losses signal ongoing operational stress, which is negative for shareholders. The equity infusion may provide short-term liquidity, but the widening losses and weak top-line raise concerns about the company's near-term financial health.